Stifel Financial Corp bought a new position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,807 shares of the medical instruments supplier’s stock, valued at approximately $1,011,000. Stifel Financial Corp owned about 0.18% of Mesa Laboratories at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its position in Mesa Laboratories by 18.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 14,223 shares of the medical instruments supplier’s stock worth $1,768,000 after buying an additional 2,247 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its position in Mesa Laboratories by 6.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 58,252 shares of the medical instruments supplier’s stock worth $7,241,000 after buying an additional 3,486 shares during the last quarter. Ranger Investment Management L.P. increased its position in Mesa Laboratories by 6.9% during the fourth quarter. Ranger Investment Management L.P. now owns 13,230 shares of the medical instruments supplier’s stock worth $1,644,000 after buying an additional 850 shares during the last quarter. BlackRock Inc. increased its position in Mesa Laboratories by 1.8% during the fourth quarter. BlackRock Inc. now owns 175,718 shares of the medical instruments supplier’s stock worth $21,843,000 after buying an additional 3,025 shares during the last quarter. Finally, DF Dent & Co. Inc. increased its position in Mesa Laboratories by 3.8% during the fourth quarter. DF Dent & Co. Inc. now owns 10,932 shares of the medical instruments supplier’s stock worth $1,359,000 after buying an additional 396 shares during the last quarter. 73.68% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have commented on the stock. BidaskClub downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. ValuEngine downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, May 22nd.
In other news, Director H Stuart Campbell sold 989 shares of the firm’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $191.17, for a total value of $189,067.13. Following the sale, the director now directly owns 41,527 shares of the company’s stock, valued at $7,938,716.59. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John James Sullivan sold 12,000 shares of the firm’s stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $197.02, for a total value of $2,364,240.00. Following the completion of the sale, the director now directly owns 74,498 shares in the company, valued at $14,677,595.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,989 shares of company stock worth $3,603,457. 15.70% of the stock is currently owned by company insiders.
Shares of NASDAQ:MLAB opened at $211.08 on Friday. The stock has a market capitalization of $776.73 million, a PE ratio of 61.99 and a beta of 0.47. Mesa Laboratories, Inc. has a 52-week low of $122.35 and a 52-week high of $214.00. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.85.
Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Tuesday, June 5th. The medical instruments supplier reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.24. The company had revenue of $26.88 million for the quarter, compared to the consensus estimate of $25.40 million. Mesa Laboratories had a positive return on equity of 12.93% and a negative net margin of 3.08%. sell-side analysts predict that Mesa Laboratories, Inc. will post 6.84 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, June 15th. Stockholders of record on Thursday, May 31st were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.30%. The ex-dividend date was Wednesday, May 30th. Mesa Laboratories’s dividend payout ratio is currently 10.36%.
Mesa Laboratories Profile
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.